Liu, Xiaofen
Huang, Chenrong
Bergen, Phillip J.
Li, Jian
Zhang, Jingjing
Chen, Yijian
Chen, Yongchuan
Guo, Beining
Hu, Fupin
Hu, Jinfang
Hu, Linlin
Li, Xin
Qiu, Hongqiang
Shao, Hua
Sun, Tongwen
Wang, Yu
Xu, Ping
Yang, Jing
Yang, Yong
Yu, Zhenwei
Zhang, Bikui
Zhu, Huaijun
Zuo, Xiaocong
Zhang, Yi
Miao, Liyan http://orcid.org/0000-0001-8481-0630
Zhang, Jing http://orcid.org/0000-0003-2966-9149
Article History
Received: 20 September 2022
Accepted: 4 December 2022
First Online: 17 February 2023
Compliance with ethics guidelines
: Jian LI licensed his new peptide antibiotics to Qpex Biopharma and has received research grants, speaking honoraria and consulting fees from Northern Antibiotics, Avexa, Genentech, Healcare, CTTQ, MedCom, Jiayou Medicine, Aosaikang, DanDi BioScience, and Qpex Biopharma. Xiaofen LIU, Chenrong HUANG, Phillip J. BERGEN, Jingjing ZHANG, Yijian CHEN, Yongchuan CHEN, Beining GUO, Fupin HU, Jinfang HU, Linlin HU, Xin LI, Hongqiang QIU, Hua SHAO, Tongwen SUN, Yu WANG, Ping XU, Jing YANG, Yong YANG, Zhenwei YU, Bikui ZHANG, Huaijun ZHU, Xiaocong ZUO, Yi ZHANG, Liyan MIAO, and Jing ZHANG declare that they have no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.